Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas

Completed · Phase 2

Conditions studied: Recurrent Glioblastoma

In brief

The purpose of this study is to evaluate both enzastaurin and bevacizumab in the treatment of recurrent malignant gliomas.

Key facts

Study ID

NCT00586508

Run by

Eli Lilly and Company

People needed

81

Starts

2007-11-01

Expected to finish

2013-10-01

Last updated by the study team

2020-09-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participant must be at least 18 years old
• Participant must have been diagnosed with a recurrent brain tumor by magnetic resonance imaging (MRI) scan
• Participant must be willing to practice adequate contraception
• Participant must be able to swallow the enzastaurin tablets whole and receive bevacizumab intravenously
• Participant must agree to use the study drug only as instructed by your study doctor and staff.

You may not qualify if…

• Women who are pregnant or breastfeeding
• Participants who have significant heart, liver, kidney, or psychiatric disease
• Participants who have an active infection
• Participants who have any recent bleeding in the brain
• Participants who are taking any anti-coagulation or anti-platelet medication [including aspirin, non-steroidal anti-inflammatories, Cyclooxygenase-2 (COX-2) inhibitors]

Where it is running

• For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.